CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Price, Quote, News and Overview
NASDAQ:CNTA - Nasdaq - US1523091007 - ADR - Currency: USD
CNTA Quote, Performance and Key Statistics
13.79
+0.18 (+1.32%)
The current stock price of CNTA is 13.79 USD. In the past month the price decreased by -4.96%. In the past year, price increased by 54.6%.
CNTA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About CNTA
Company Profile
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 77 full-time employees. The company went IPO on 2021-05-28. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. The company is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Company Info
CENTESSA PHARMACEUTICALS-ADR
3rd Floor, 1 Ashley Road
Altrincham CHESHIRE GB
CEO: Saurabh Saha
Employees: 72
Company Website: https://www.centessa.com/
Investor Relations: https://investors.centessa.com/
Phone: 447391789784
CENTESSA PHARMACEUTICALS-ADR / CNTA FAQ
What is the stock price of CENTESSA PHARMACEUTICALS-ADR today?
The current stock price of CNTA is 13.79 USD. The price increased by 1.32% in the last trading session.
What is the ticker symbol for CENTESSA PHARMACEUTICALS-ADR stock?
The exchange symbol of CENTESSA PHARMACEUTICALS-ADR is CNTA and it is listed on the Nasdaq exchange.
On which exchange is CNTA stock listed?
CNTA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CENTESSA PHARMACEUTICALS-ADR stock?
16 analysts have analysed CNTA and the average price target is 32.39 USD. This implies a price increase of 134.84% is expected in the next year compared to the current price of 13.79. Check the CENTESSA PHARMACEUTICALS-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CENTESSA PHARMACEUTICALS-ADR worth?
CENTESSA PHARMACEUTICALS-ADR (CNTA) has a market capitalization of 1.84B USD. This makes CNTA a Small Cap stock.
How many employees does CENTESSA PHARMACEUTICALS-ADR have?
CENTESSA PHARMACEUTICALS-ADR (CNTA) currently has 72 employees.
What are the support and resistance levels for CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?
CENTESSA PHARMACEUTICALS-ADR (CNTA) has a support level at 11.56 and a resistance level at 13.8. Check the full technical report for a detailed analysis of CNTA support and resistance levels.
Should I buy CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CNTA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CNTA, evaluating the profitability, health, valuation and growth aspects
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Sales and EPS estimates to see what analysts future expectations are.
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Chart to make your own analysis
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Latest news and press-releases to stay up to date.
Does CENTESSA PHARMACEUTICALS-ADR (CNTA) stock pay dividends?
CNTA does not pay a dividend.
What is the Price/Earnings (PE) ratio of CENTESSA PHARMACEUTICALS-ADR (CNTA)?
CENTESSA PHARMACEUTICALS-ADR (CNTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.73).
What is the Short Interest ratio of CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?
The outstanding short interest for CENTESSA PHARMACEUTICALS-ADR (CNTA) is 3.79% of its float. Check the ownership tab for more information on the CNTA short interest.
CNTA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CNTA. When comparing the yearly performance of all stocks, CNTA is one of the better performing stocks in the market, outperforming 90.77% of all stocks.
CNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTA. While CNTA seems to be doing ok healthwise, there are quite some concerns on its profitability.
CNTA Financial Highlights
Over the last trailing twelve months CNTA reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS decreased by -10.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.87% | ||
| ROE | -58.71% | ||
| Debt/Equity | 0.27 |
CNTA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to CNTA. The Buy consensus is the average rating of analysts ratings from 16 analysts.